Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -54.75% is 91% above its 5-year average of -588.21%, near the high end of its 5-year range (-1270883.33%–214.09%).
99.00% above its 12-month average of -5498.01%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -25036.33%.
NET PROFIT MARGIN
-54.75%
NET PROFIT MARGIN AVG TTM
-5498.01%
NET PROFIT MARGIN AVG 3Y
-660.39%
NET PROFIT MARGIN AVG 5Y
-588.21%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.00%
CURRENT VS 3Y AVG
+91.71%
CURRENT VS 5Y AVG
+90.69%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
8.68%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
-730.76%
vs the sector median at left
Beam Therapeutics Inc.
Market Cap
$2.51B
Net Profit Margin
-54.75%
TTM Avg
-5498.01%
3Y Avg
-660.39%
5Y Avg
-588.21%
Market Cap
$2.74B
Net Profit Margin
22.69%
TTM Avg
19.73%
3Y Avg
-2.42%
5Y Avg
-44.65%
Market Cap
$2.14B
Net Profit Margin
-945.92%
TTM Avg
-825.68%
3Y Avg
-750.64%
5Y Avg
-1236.10%
Market Cap
$1.73B
Net Profit Margin
-14.99%
TTM Avg
-20.12%
3Y Avg
-16.95%
5Y Avg
-10.04%
Market Cap
$1.72B
Net Profit Margin
-672.16%
TTM Avg
-753.31%
3Y Avg
-935.73%
5Y Avg
-797.48%
Market Cap
$1.00B
Net Profit Margin
-7.13%
TTM Avg
-23.45%
3Y Avg
-155.72%
5Y Avg
-114.72%
Market Cap
$472.39M
Net Profit Margin
-6.77%
TTM Avg
-13.38%
3Y Avg
-17.48%
5Y Avg
-11.79%
Market Cap
$397.55M
Net Profit Margin
-58.33%
TTM Avg
-67.34%
3Y Avg
-66.78%
5Y Avg
-66.78%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.51B | -54.75% | -5498.01% | -660.39% | -588.21% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 22.69% | 19.73% | -2.42% | -44.65% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | -945.92% | -825.68% | -750.64% | -1236.10% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | -14.99% | -20.12% | -16.95% | -10.04% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | -672.16% | -753.31% | -935.73% | -797.48% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | -7.13% | -23.45% | -155.72% | -114.72% |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | -6.77% | -13.38% | -17.48% | -11.79% |
| NRC Health (NRC)vs › | $459.30M | 4.18% | 12.88% | 16.89% | 20.14% |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | -58.33% | -67.34% | -66.78% | -66.78% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-274.6%
Net Profit Margin
-54.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -25036.33% |
| 2026-03-31 | -297.18% |
| 2025-12-31 | 214.09% |
| 2025-09-30 | -1162.38% |
| 2025-06-30 | -1208.26% |
| 2025-03-31 | -1462.78% |
| 2024-12-31 | -300.51% |
| 2024-09-30 | -677.47% |
| 2024-06-30 | -773.45% |
| 2024-03-31 | -1331.57% |
| 2023-12-31 | 45.16% |
| 2023-09-30 | -558.88% |
| 2023-06-30 | -411.49% |
| 2023-03-31 | -398.46% |
| 2022-12-31 | -191.39% |
| 2022-09-30 | -693.56% |
| 2022-06-30 | -432.08% |
| 2022-03-31 | -820.85% |
| 2021-12-31 | -126.71% |
| 2021-09-30 | -3685.19% |
| 2021-06-30 | -1270883.33% |
| 2021-03-31 | -3359333.33% |
| 2020-12-31 | -1591066.67% |
| 2020-09-30 | -574200.00% |
| 2020-06-30 | -570300.00% |
| 2020-03-31 | -507633.33% |
| 2019-12-31 | -464166.67% |
| 2019-09-30 | -316750.00% |
| 2019-06-30 | -297683.33% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
